Clinical Trials Logo

Follicular Lymphoma clinical trials

View clinical trials related to Follicular Lymphoma.

Filter by:

NCT ID: NCT03498612 Active, not recruiting - Follicular Lymphoma Clinical Trials

Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Start date: July 9, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with B-cell non-Hodgkin lymphoproliferative diseases that have not been treated. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03436602 Active, not recruiting - Follicular Lymphoma Clinical Trials

Personalized Risk Stratification Model of Follicular Lymphoma Patients

Start date: March 1, 2018
Phase:
Study type: Observational

The study aims at developping and validating an integrated clinico-molecular model for an accurate identification of FL patients who are progression free and progressed, respectively, at 24 months after treatment.

NCT ID: NCT03424603 Active, not recruiting - Multiple Myeloma Clinical Trials

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

NCT ID: NCT03361852 Active, not recruiting - Follicular Lymphoma Clinical Trials

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Start date: March 14, 2022
Phase: Phase 1
Study type: Interventional

This research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL). The agents involved in this study are: - Rituximab - Personalized NeoAntigen vaccine - Poly-ICLC - Pembrolizumab

NCT ID: NCT03245021 Active, not recruiting - Follicular Lymphoma Clinical Trials

Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A

1stFLOR
Start date: September 7, 2017
Phase: Phase 1
Study type: Interventional

Firstline treatment for grade 13a Follicular Lymphoma using Opdivo (nivolumab) plus Rituximab: The 1st FLOR trial

NCT ID: NCT03162536 Active, not recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Start date: June 26, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

NCT ID: NCT03133221 Active, not recruiting - Follicular Lymphoma Clinical Trials

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Start date: October 23, 2017
Phase: Phase 2
Study type: Interventional

This is a pilot study to learn how safe and how effective the study drug Zydelig works, after autologous stem cell transplant as a maintenance therapy in patients with indolent or transformed indolent B-cell non-Hodgkins lymphoma (iNHL or tiNHL).

NCT ID: NCT03105336 Active, not recruiting - Follicular Lymphoma Clinical Trials

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

ZUMA-5
Start date: June 20, 2017
Phase: Phase 2
Study type: Interventional

This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the participants own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.

NCT ID: NCT03078855 Active, not recruiting - Follicular Lymphoma Clinical Trials

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

ILyAD
Start date: September 7, 2017
Phase: Phase 3
Study type: Interventional

Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in the blood, through supplementation, can improve outcomes.

NCT ID: NCT02947347 Active, not recruiting - Follicular Lymphoma Clinical Trials

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Start date: January 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve participants with follicular lymphoma.